Choroideremia Treatment Market size is estimated to reach USD 33 billion by the end of 2036, expanding around 5% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of choroideremia treatment was over USD 9 billion.
The growth of this market can be ascribed to the increasing prevalence of choroideremia all across the globe. 1 in 50,000 to 100,000 people in the United States has choroideremia according to the Centers for Disease Control and Prevention.
Due to the delay in diagnosis and treatment of patients with choroideremia, COVID-19 is likely to have an important effect on the therapeutic market for choroideremia. Anyhow, the result will be short-term and post-COVID-19 pandemic, the choroideremia treatment market will show a significant surge owing to an increase in treatment adoption.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 - 2036 |
|
CAGR |
5% |
|
Base Year Market Size (2023) |
USD 9 billion |
|
Forecast Year Market Size (2036) |
USD 33 billion |
|
Regional Scope |
|
Route of Administration (Oral, Intravenous, Ophthalmic)
In choroideremia treatment market, ophthalmic segment is likely to account for around 40% share by 2036. The growth of this segment can be attributed on account of increasing integration of gene therapy in ophthalmic route of administration.
Gene therapy is regarded as a promising approach for treating choroideremia and its adoption is anticipated to rise in the upcoming years. This is owing to factors such as enhanced safety and efficacy profiles of gene therapy vectors and increasing clinical trial data supporting its effectiveness. Biogen Inc. initiated a Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharmacies)
In choroideremia treatment market, hospital pharmacies segment is predicted to hold more than 40% revenue share by 2036. Hospital pharmacies often serve as the central distribution point for specialized and high-cost medications such as those targeted for rare diseases like choroideremia.
This efficiency in supply chain management could benefit patients by ensuring timely access to treatment. Furthermore, as new choroideremia treatments especially gene therapy approaches reach the market, innovative reimbursement pathways are being explored. Hospital pharmacies are likely to play a crucial role in navigating these play a key role in navigating these reimbursement complexities and facilitating patient access to treatment.
Our in-depth analysis of the global choroideremia treatment market includes the following segments:
|
Therapy |
|
|
Administration |
|
|
Distribution Channel |
|
North American Market Forecast
By 2036, North America region is projected to account for around 35% choroideremia treatment market share. North America is an epicenter of innovation and technology that has helped the region establish itself as a leader in the healthcare industry.
This is also true for the market for choroideremia treatments in North America, where developments in R&D are propelling the industry to new heights. A number of clinical centres that focus on the diagnosis and treatment of choroideremia could potentially account for the growth. Numerous services are provided by these centres, including genetic testing, rehabilitation for individuals with limited vision, and access to experimental medications like gene therapy.
For occasion, the Choroideremia Inquire about Establishment CRFC is a nongovernmental organization committed to financing and investigating on potential medications and cures for Choroideremia in Canada
APAC Market Statistics
The market in the Asia Pacific region is predicted to grow significantly by the end of 2036. The Asia Pacific region is experiencing rapid economic growth leading to escalating disposable incomes in many countries. This makes patients more willing and able to afford costly choroideremia treatments.
Governments in the region are also investing highly in infrastructure, making advanced treatments more accessible to patients. Furthermore, recent advancements in gene therapy and optogenetics hold promise for the development of more effective treatments for choroideremia. Several clinical trials are currently underway in the Asia Pacific region for novel therapies that could boost growth of the choroideremia treatment market in the future.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?